Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Suzhou Guochen Biotechnology Co., Ltd. | Jeeyor Medical Research | Boji Medical Technology | The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HY-2003
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2025
Lead Product(s) : HY-2003
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Peking Union Medical College Hospital | First Affiliated Hospital Xi'an Jiaotong University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HYP-6589
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : HYP-6589
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Iron Sucrose Injection in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2024
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HY07121
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : HY07121
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Iron Sucrose Injection in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HYP-2090PTSA
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : HYP-2090PTSA
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 12, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : The First Hospital of Jilin University | Suzhou Guochen Biotek Co., Ltd. | Boji Data Technology | Boji Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable